The takeover battle between two Canadian cannabis companies has finally ended.
Aurora Cannabis Inc.
(TSX: ACB,
OTCQB: ADBFF,
Forum) completed its acquisition of former rival CanniMed Therapeutics.
The licensed marijuana producing giant announced that it had acquired all of the outstanding CanniMed shares it didn’t already own. CanniMed’s shares have been delisted from the Toronto Stock Exchange by the close of trading on Monday.
For more on this acquisition, click
here.
Aurora bought CanniMed in January 2018 in a stock-and-cash deal valued at $1.1 billion. CanniMed will still operate as a wholly-owned subsidiary of Aurora and continue its research and product development.